Suppliers and packagers for desferal

desferal

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Mitem Pharma	DESFERAL	deferoxamine mesylate	INJECTABLE;INJECTION	016267	NDA	Novartis Pharmaceuticals Corporation	0078-0467-91	4 VIAL in 1 CARTON (0078-0467-91) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL (0078-0467-61)	1968-04-02
Mitem Pharma	DESFERAL	deferoxamine mesylate	INJECTABLE;INJECTION	016267	NDA	MITEM PHARMA	87081-467-91	4 mL in 1 VIAL (87081-467-91)	1968-04-02

Desferal Suppliers: Market Analysis and Sourcing Considerations

Last updated: February 19, 2026

This report analyzes the global supply landscape for desferrioxamine mesylate (Desferal), a critical chelating agent used in treating iron and aluminum overload. The analysis identifies key manufacturers, assesses market dynamics, and outlines critical considerations for pharmaceutical companies seeking reliable sourcing.

Who Are the Primary Manufacturers of Desferal?

The production of desferrioxamine mesylate is concentrated among a limited number of global pharmaceutical ingredient manufacturers. These entities possess the specialized chemical synthesis capabilities and regulatory approvals necessary to produce this complex molecule.

Key manufacturers include:

• Novartis AG: As the originator and primary brand holder of Desferal (ironically, now marketed under various brand names and as a generic), Novartis has historically been a central player in its supply chain. While they may not be the sole producer of the active pharmaceutical ingredient (API) for all global markets, their historical involvement and ongoing regulatory oversight remain significant.
• Indian API Manufacturers: A substantial portion of generic Desferal API production originates from India. Companies like:
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Ltd. These companies have established capabilities in complex API synthesis and have secured regulatory approvals in major markets, including the U.S. and Europe.
• Chinese API Manufacturers: Several Chinese pharmaceutical chemical companies also contribute to the global Desferal API supply. Due diligence is crucial when engaging with these suppliers to ensure consistent quality and regulatory compliance. Specific company names are often subject to change and require direct market intelligence.

The manufacturing process for desferrioxamine mesylate involves fermentation using the bacterium Streptomyces pilosus, followed by complex chemical isolation and purification steps. This intricate process contributes to the limited number of manufacturers with the requisite expertise and infrastructure.

What Are the Market Dynamics for Desferal API?

The market for Desferal API is characterized by a balance between demand for a critical therapeutic and the realities of a mature generic drug market.

• Demand Drivers:
  • Thalassemia and Myelodysplastic Syndromes: These inherited blood disorders necessitate chronic blood transfusions, leading to iron overload. Desferal is a cornerstone therapy.
  • Aluminum Toxicity: Patients with chronic kidney disease on hemodialysis can develop aluminum toxicity, which Desferal can effectively treat.
  • Orphan Drug Status Considerations: While not always officially designated as an orphan drug globally, the patient population for Desferal-treated conditions is relatively small compared to blockbuster drugs, influencing market size and investment focus.
• Supply Chain Concentration: The reliance on a few key API manufacturers, particularly in India, creates potential vulnerabilities. Geopolitical events, regulatory changes, or production issues at a single large supplier can impact global availability.
• Pricing Pressures: As a well-established generic, Desferal API is subject to pricing pressures from generic drug manufacturers and healthcare systems focused on cost containment. This can influence the profitability and investment in R&D for API process optimization by manufacturers.
• Regulatory Scrutiny: Like all pharmaceutical APIs, Desferal is subject to stringent quality control and regulatory oversight by bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Manufacturers must maintain current Good Manufacturing Practices (cGMP) and possess approved Drug Master Files (DMFs).
• Geographic Distribution: API production is largely concentrated in India and China, with some historical or niche production potentially occurring in Europe. Finished dosage form manufacturing is more geographically dispersed, including North America, Europe, and Asia.

What Are the Key Considerations for Sourcing Desferal API?

Pharmaceutical companies looking to secure a stable and high-quality supply of Desferal API must undertake rigorous due diligence across several critical areas.

Regulatory Compliance and Quality Assurance

• Drug Master File (DMF) Status: Confirm the API manufacturer's DMF is active and accepted by target regulatory authorities (FDA, EMA, etc.). Review the DMF for completeness and any recent deficiency letters or inspection findings.
• cGMP Compliance: The manufacturing site must adhere to current Good Manufacturing Practices. This involves regular audits of the facility by the procuring company and verification of recent inspection reports from regulatory agencies.
• Quality Control (QC) Testing: Establish clear specifications for API purity, impurity profiles, assay, and physical characteristics. Ensure the manufacturer's QC capabilities meet or exceed these specifications and that a robust Certificate of Analysis (CoA) system is in place.
• Impurity Profiling: Pay close attention to the potential for process-related impurities and degradation products. Understanding and controlling these is vital for patient safety. Specific limits for known impurities should be defined.
• Stability Studies: Review the manufacturer's stability data to understand the API's shelf life under recommended storage conditions.

Supply Chain Resilience and Reliability

• Manufacturing Capacity: Assess the manufacturer's production capacity and their ability to scale up to meet projected demand. Understand their batch sizes and production schedules.
• Business Continuity Planning: Inquire about the manufacturer's business continuity and disaster recovery plans, especially concerning raw material sourcing, geopolitical risks, and potential production disruptions.
• Multiple Supplier Strategy: For critical drugs like Desferal, consider qualifying at least two API suppliers to mitigate single-source dependency risks.
• Lead Times and Inventory Management: Establish clear expectations for order lead times and explore consignment inventory or safety stock agreements to buffer against unexpected supply fluctuations.
• Geographic Diversification: If feasible, consider suppliers located in different geographic regions to mitigate risks associated with regional events.

Technical and Process Considerations

• Synthesis Route: Understand the API's manufacturing process. Changes to the synthesis route can impact impurity profiles and require revalidation.
• Raw Material Sourcing: Identify the origin and quality control of key starting materials and intermediates used in Desferal synthesis. Dependence on single suppliers for these can also pose risks.
• Intellectual Property (IP): Ensure the chosen API manufacturer has clear rights to produce and sell the API, especially concerning any process patents.
• Packaging and Storage: Verify that the API is packaged in appropriate, inert materials that maintain its stability and integrity during transit and storage.

Financial and Commercial Aspects

• Pricing and Payment Terms: Negotiate competitive pricing and clear payment terms. Understand price escalation clauses and their triggers.
• Contractual Agreements: Execute comprehensive supply agreements that clearly define quality standards, delivery schedules, responsibilities, indemnification, and termination clauses.
• Auditing Capabilities: Ensure the supplier allows for regular quality and business audits by the procuring company.

Desferal API Manufacturers Overview

Manufacturer	Country of Origin	Primary Market Focus	Notes
Novartis AG	Switzerland	Global	Originator company; may supply API or finished product. Historical market leader.
Sun Pharmaceutical Industries Ltd.	India	Global	Significant generic API producer with extensive regulatory filings.
Lupin Ltd.	India	Global	Established API manufacturer with a strong presence in regulated markets.
Dr. Reddy's Laboratories Ltd.	India	Global	Renowned for API development and manufacturing; holds multiple DMFs.
Cipla Ltd.	India	Global	A major Indian pharmaceutical company with significant API manufacturing capabilities.
Various Chinese Manufacturers	China	Global	Multiple entities produce Desferal API; requires rigorous supplier qualification and ongoing oversight. Specific company names vary.

Note: This table represents prominent and historically significant players. The landscape is dynamic, with potential for new entrants and changes in market share. Direct engagement with market intelligence firms is recommended for the most current supplier list.

Key Takeaways

• The global supply of Desferal API is primarily concentrated among a limited number of Indian and, to a lesser extent, Chinese manufacturers, alongside the historical involvement of Novartis.
• Demand for Desferal is driven by chronic iron overload conditions like thalassemia and myelodysplastic syndromes, and aluminum toxicity in renal patients.
• Securing a reliable Desferal supply chain necessitates a robust focus on regulatory compliance (cGMP, DMFs), stringent quality assurance, and comprehensive supply chain risk mitigation strategies, including potential dual-sourcing.
• Due diligence must extend to understanding the API's synthesis route, raw material sourcing, and the manufacturer's business continuity planning.

Frequently Asked Questions

1. Are there alternative chelating agents to Desferal for iron overload? Yes, oral iron chelators such as deferasirox (Exjade, Jadenu) and deferiprone (Ferriprox) are alternatives, particularly for patients who cannot tolerate or adhere to parenteral Desferal therapy.

2. What are the typical impurities to monitor in Desferal API? Key impurities can include related substances from the fermentation process, degradation products, and process-related impurities such as residual solvents. Specific limits are defined in pharmacopeias (e.g., USP, EP) and regulatory filings.

3. How does the regulatory status of Desferal API vary by region? API manufacturers must obtain approval for their Drug Master Files (DMFs) or equivalent submissions in each target market. Approval by the US FDA and the EMA are critical for access to major pharmaceutical markets.

4. What is the typical shelf life for Desferal API? The shelf life of Desferal API is generally determined by stability studies conducted by the manufacturer, often ranging from 2 to 5 years when stored under specified conditions. Exact shelf life should be confirmed via the Certificate of Analysis and manufacturer documentation.

5. Can a single manufacturer meet the global demand for Desferal API? While a few large manufacturers possess significant capacity, global demand is substantial. Relying on a single supplier poses a considerable risk, and a multi-supplier strategy is advisable for long-term supply security.

Citations

[1] United States Pharmacopeia. (2023). Desferrioxamine Mesylate. In USP-NF. Retrieved from [USP-NF Online Access - Requires Subscription] (Note: Specific access to USP-NF requires subscription. Information is publicly available via general searches on pharmacopeial standards). [2] European Medicines Agency. (2023). Desferrioxamine. Retrieved from [EMA Website] (Note: Specific search on EMA website for desferrioxamine can yield product information and regulatory status for approved medicines). [3] Various Company Investor Relations and Product Information Websites. (Accessed 2023).